BioNTech Partner's Drug Candidate Faces FDA Clinical Hold
Ticker: BNTX · Form: 6-K · Filed: 2024-10-18T00:00:00.000Z
Sentiment: bearish
Topics: clinical-hold, fda, drug-development, partnership
Related Tickers: BNTX
TL;DR
FDA puts BioNTech partner's cancer drug ONC-390 on clinical hold, halting trials.
AI Summary
BioNTech SE announced on October 18, 2024, that its partner OncoC4, Inc. has been informed by the U.S. Food and Drug Administration (FDA) regarding the investigational new drug (IND) application for ONC-390, a novel antibody targeting the C4 complement protein. The FDA has placed a clinical hold on the IND application, meaning further clinical trials for ONC-390 cannot proceed until specific issues are resolved.
Why It Matters
This FDA clinical hold on ONC-390 could delay BioNTech's potential revenue from this drug candidate and impacts the development timeline for a new cancer therapy.
Risk Assessment
Risk Level: medium — A clinical hold introduces significant uncertainty and delays for a drug candidate, potentially impacting future revenue and market entry.
Key Players & Entities
- BioNTech SE (company) — Registrant and partner's collaborator
- OncoC4, Inc. (company) — BioNTech's partner
- U.S. Food and Drug Administration (FDA) (company) — Regulator that placed the clinical hold
- ONC-390 (drug_candidate) — Investigational drug targeting C4 complement protein
- October 18, 2024 (date) — Date of the announcement
FAQ
What is the specific reason for the FDA's clinical hold on ONC-390?
The filing states that the FDA has placed a clinical hold on the IND application for ONC-390, but does not specify the exact reasons for the hold.
What is the role of BioNTech SE in relation to ONC-390?
BioNTech SE is the partner of OncoC4, Inc., the company developing ONC-390.
What is ONC-390?
ONC-390 is a novel antibody developed by OncoC4, Inc. that targets the C4 complement protein.
When was this information disclosed?
This information was disclosed in a Form 6-K filed with the SEC on October 18, 2024.
What is the immediate impact of the clinical hold?
The immediate impact of the clinical hold is that further clinical trials for ONC-390 cannot proceed until the issues raised by the FDA are resolved.
From the Filing
0001776985-24-000085.txt : 20241018 0001776985-24-000085.hdr.sgml : 20241018 20241018090429 ACCESSION NUMBER: 0001776985-24-000085 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241018 FILED AS OF DATE: 20241018 DATE AS OF CHANGE: 20241018 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 241378979 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kbnt31618oct2024.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ INFORMATION INCLUDED AS PART OF THIS FORM 6-K BioNTech SE (“BioNTech”) has been informed by its partner OncoC4, Inc. (“OncoC4”) that the U.S. Food and Drug Administration (“FDA”) has placed a partial clinical hold on the companies’ two-stage, open-label, randomized Phase 3 trial, PRESERVE-003 (NCT05671510). BioNTech and OncoC4 understand that the partial clinical hold in the ongoing Phase 3 trial with BNT316/ONC-392 (gotistobart) in non-small cell lung cancer (“NSCLC”) is due to varying results between the squamous and non-squamous NSCLC patient populations. The trial evaluates the efficacy and safety of the antibody candidate BNT316/ONC-392 as monotherapy in patients with metastatic NSCLC that progressed under previous PD-(L)1-inhibitor treatment. A recent assessment of the trial data by the independent data monitoring committee identified a possible variance in population results. Consequently, OncoC4 and BioNTech decided to proactively pause enrollment of new patients and informed the FDA of the possible variance for further alignment. While the companies are assessing next steps for the ongoing trial with BNT316/ONC-392 in NSCLC, patients already enrolled in the trial will continue to receive treatment. Trials evaluating BNT316/ONC-392 in other indications remain unaffected. About BNT316/ONC-392 (gotistobart) BNT316/ONC-392 (gotistobart) is a next-generation anti-CTLA-4 antibody candidate jointly being developed by BioNTech and OncoC4. BNT316/ONC-392 is currently in late-stage clinical development as monotherapy or combination therapy in various cancer indications. The immune checkpoint receptor CTLA-4 inhibits T cell immune response and reduces the activity of T cells in recognizing and eliminating cancer cells. This mechanism is also exploited by cancer cells to prevent them from being eliminated by T cells. Blocking CTLA-4 may help to preserve T cell activity and enhance anti-tumor activity. BNT316/ONC-392 was designed with the aim to address this mechanism while preserving CTLA-4 recycling and thus the immunosuppressive T cell (regulatory T cells, or “Tregs”